Harrow Health 8625 Stock Working Capital
| HROWL Stock | USD 25.39 0.06 0.24% |
Harrow Health 8625 fundamentals help investors to digest information that contributes to Harrow Health's financial success or failures. It also enables traders to predict the movement of Harrow Stock. The fundamental analysis module provides a way to measure Harrow Health's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Harrow Health stock.
| Last Reported | Projected for Next Year | ||
| Change In Working Capital | -7.1 M | -6.8 M |
Harrow | Working Capital |
Harrow Health 8625 Company Working Capital Analysis
Harrow Health's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Harrow Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Harrow Health is extremely important. It helps to project a fair market value of Harrow Stock properly, considering its historical fundamentals such as Working Capital. Since Harrow Health's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Harrow Health's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Harrow Health's interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Harrow Capital Surpluse
Capital Surpluse |
|
According to the company's disclosures, Harrow Health 8625 has a Working Capital of 0.0. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Harrow Health Current Valuation Drivers
We derive many important indicators used in calculating different scores of Harrow Health from analyzing Harrow Health's financial statements. These drivers represent accounts that assess Harrow Health's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Harrow Health's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 197.0M | 177.6M | 231.2M | 405.3M | 365.3M | 383.6M | |
| Enterprise Value | 213.3M | 197.1M | 267.0M | 413.2M | 481.7M | 505.8M |
Harrow Health ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Harrow Health's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Harrow Health's managers, analysts, and investors.Environmental | Governance | Social |
Harrow Fundamentals
| Return On Equity | 0.45 | ||||
| Number Of Shares Shorted | 314 | ||||
| Revenue | 130.19 M | ||||
| EBITDA | 9.72 M | ||||
| Net Income | (24.41 M) | ||||
| Total Debt | 190.5 M | ||||
| Cash Flow From Operations | 3.84 M | ||||
| Market Capitalization | 247.48 M | ||||
| Total Asset | 312.16 M | ||||
| Retained Earnings | (133.9 M) | ||||
| Net Asset | 312.16 M |
About Harrow Health Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Harrow Health 8625's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harrow Health using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harrow Health 8625 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Harrow Health Piotroski F Score and Harrow Health Altman Z Score analysis. For more information on how to buy Harrow Stock please use our How to buy in Harrow Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harrow Health. If investors know Harrow will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harrow Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Equity 0.4484 |
The market value of Harrow Health 8625 is measured differently than its book value, which is the value of Harrow that is recorded on the company's balance sheet. Investors also form their own opinion of Harrow Health's value that differs from its market value or its book value, called intrinsic value, which is Harrow Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harrow Health's market value can be influenced by many factors that don't directly affect Harrow Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harrow Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harrow Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harrow Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.